TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23357834

Group type: EXPERIMENTAL
Intervention: Tapentadol IR 86 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tapentadol PR 86 mg
Number of subjects: 24
Study: 21276280

Group type: EXPERIMENTAL
Intervention: Astaxanthin 6 mg/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Astaxanthin 12 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19246457

Group type: EXPERIMENTAL
Intervention: Acustimulation (n=101)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sham stimulation (n=99)
Number of subjects: 200
Study: 17210732

Group type: EXPERIMENTAL
Intervention: 100 microg of morphine (MS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PLCB)
Number of subjects: 60
Study: 15233702

Group type: EXPERIMENTAL
Intervention: Continuous tegaserod treatment
Number of subjects: 500

Group type: COMPARATOR
Intervention: Intermittent treatment
Number of subjects: 500

Group type: COMPARATOR
Intervention: Withdrawal of treatment
Number of subjects: 500
Study: 11046209

Group type: EXPERIMENTAL
Intervention: 10 mg/kg ketamine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 1 mg/kg midazolam
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 5 mg/kg ketamine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 7 mg/kg ketamine
Number of subjects: 66
Study: 9504815

Group type: EXPERIMENTAL
Intervention: Two-dimensional protein map of amniotic fluid proteins using IPG/SDS‐PAGE technique
Number of subjects: 0
Study: 7828457

Group type: EXPERIMENTAL
Intervention: amikacin (AK) 15 mg/kg/day q.d. (n = 10)
Number of subjects: 22

Group type: COMPARATOR
Intervention: amikacin (AK) b.i.d. (n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (8 healthy neonates)
Number of subjects: 22
Study: 2875593

Group type: EXPERIMENTAL
Intervention: Lormetazepam 2 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lormetazepam
Number of subjects: 60
Study: 29645359

Group type: COMPARATOR
Intervention: Fatty Fish (FF)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Camelina Sativa Oil (CSO)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Lean Fish (LF)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study: 26454186

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT) intervention, n=104
Number of subjects: 205

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) control, n=101
Number of subjects: 205
Study: 24272416

Group type: EXPERIMENTAL
Intervention: Pivotal Response Training (PRT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Picture Exchange Communication System (PECS)
Number of subjects: 39
Study: 22415082

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 22
Study: 20110289

Group type: EXPERIMENTAL
Intervention: Isolated hepatic perfusion (IHP) with melphalan
Number of subjects: 99

Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 99
Study: 18803728

Group type: EXPERIMENTAL
Intervention: Micronutrient fortified cooked lunch meals
Number of subjects: 181

Group type: COMPARATOR
Intervention: Unfortified cooked lunch meals
Number of subjects: 181
Study: 15855695

Group type: EXPERIMENTAL
Intervention: Adrenal androgen-DHEAS
Number of subjects: 57
Study: 12651674

Group type: EXPERIMENTAL
Intervention: Esmolol (0.3 mg. kg(‐1). min(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11062382

Group type: EXPERIMENTAL
Intervention: 500 mg QD flutamide
Number of subjects: 440

Group type: COMPARATOR
Intervention: 250 mg q8h flutamide
Number of subjects: 440
Study: 8960395

Group type: EXPERIMENTAL
Intervention: Nitroglycerine (100 ng/min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Dextrose (control)
Number of subjects: 14
Study: 1436563

Group type: EXPERIMENTAL
Intervention: Chlorhydrate nefopam
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 3781500

Group type: EXPERIMENTAL
Intervention: Outpatient mental health services
Number of subjects: 4254

Group type: EXPERIMENTAL
Intervention: Any provider for mental health care
Number of subjects: 4254

Group type: EXPERIMENTAL
Intervention: General medical providers
Number of subjects: 4254

Group type: EXPERIMENTAL
Intervention: Annual outpatient mental health expenses
Number of subjects: 4254
Study: 29937265

Group type: EXPERIMENTAL
Intervention: Spring Element Systems (SES)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional Systems (CS)
Number of subjects: 29
Study: 27310989

Group type: EXPERIMENTAL
Intervention: OLV with adjustable ventilation parameters (OLV-AP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: OLV with preset ventilation parameters (OLV-PP)
Number of subjects: 30
Study: 23471544

Group type: EXPERIMENTAL
Intervention: PTSD treatment
Number of subjects: 150
Study: 22961516

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg intravenous)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study: 21677124

Group type: EXPERIMENTAL
Intervention: HIGH (≥1200 mg calcium)
Number of subjects: 29

Group type: COMPARATOR
Intervention: LOW (≤500 mg calcium)
Number of subjects: 29
Study: 18826631

Group type: EXPERIMENTAL
Intervention: Breast cancer patients
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Breast cancer patients post-tumor excision
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Postmenopausal breast cancer patients with previous hysterectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Controls (matched for age, menopausal and hysterectomy status)
Number of subjects: 200
Study: 16054823

Group type: EXPERIMENTAL
Intervention: Ropivacaine-sufentanil infusion (Group SR, n=31)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ropivacaine infusion (Group R, n=31)
Number of subjects: 62
Study: 11252549

Group type: EXPERIMENTAL
Intervention: efavirenz-containing triple therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: indinavir-containing triple therapy
Number of subjects: 0
Study: 9628275

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg once daily for 8 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: Troglitazone and Placebo
Number of subjects: 15
Study: 7882656

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste (0.15% F) for home use every second month
Number of subjects: 206

Group type: COMPARATOR
Intervention: Supervised fluoride rinsing with 0.2% sodium fluoride and supervised toothbrushings
Number of subjects: 206
Study: 3337652

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative breathing exercises supervised by a physical therapist
Number of subjects: 153

Group type: COMPARATOR
Intervention: No breathing exercises (Control group)
Number of subjects: 153
Study: 1957991

Group type: EXPERIMENTAL
Intervention: Immunotherapy with Olea europaea extracts
Number of subjects: 37

Group type: COMPARATOR
Intervention: Drug therapy (control group)
Number of subjects: 37
Study: 14816

Group type: EXPERIMENTAL
Intervention: Atenolol (200 mg daily for five weeks)
Number of subjects: 16
Study: 30814109

Group type: EXPERIMENTAL
Intervention: lapatinib at T0
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: lapatinib at T1
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: trastuzumab at T1
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: lapatinib+trastuzumab at T1
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: ct-miR-140-5p (part of trastuzumab signature)
Number of subjects: 429
Study: 27862477

Group type: EXPERIMENTAL
Intervention: Data-driven model for reaction prediction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rule-based expert system
Number of subjects: 0
Study: 25703475

Group type: EXPERIMENTAL
Intervention: Transepithelial CXL with Ricrolin TE
Number of subjects: 61

Group type: COMPARATOR
Intervention: Epi-off CXL with isotonic riboflavin
Number of subjects: 61
Study: 23957727

Group type: EXPERIMENTAL
Intervention: Instrumented posterolateral lumbar fusion with spondylolisthesis reduction
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 72
Study: 25426896

Group type: EXPERIMENTAL
Intervention: Ozonated oil (2 mL daily for 1 week)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 18
Study: 18036682

Group type: EXPERIMENTAL
Intervention: Nordic pole walking (NW)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional walking
Number of subjects: 48
Study: 17260365

Group type: EXPERIMENTAL
Intervention: Reviparin 3,436 IU subcutaneously twice daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 15726328

Group type: EXPERIMENTAL
Intervention: Abrasive arthroplasty
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Periosteal arthroplasty
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 30
Study: 11694152

Group type: EXPERIMENTAL
Intervention: Estrogen use alone
Number of subjects: 25665

Group type: EXPERIMENTAL
Intervention: Estrogen plus progesterone/progestin use
Number of subjects: 25665

Group type: EXPERIMENTAL
Intervention: HRT use (any type)
Number of subjects: 25665

Group type: COMPARATOR
Intervention: No HRT use
Number of subjects: 25665
Study: 9109726

Group type: EXPERIMENTAL
Intervention: buccal bioadhesive slow‐release tablet containing miconazole nitrate
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 8197766

Group type: EXPERIMENTAL
Intervention: Immediate prophylactic radiotherapy (DXT group)
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Control (WP group)
Number of subjects: 2800
Study: 3296794

Group type: EXPERIMENTAL
Intervention: Brief stop smoking advice by physicians
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 258
Study: 31340534

Group type: EXPERIMENTAL
Intervention: 250 mg of CurcuWIN® (50 mg of curcuminoids)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 1000 mg of CurcuWIN® (200 mg of curcuminoids)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Corn starch placebo (PLA)
Number of subjects: 63
Study: 28857237

Group type: EXPERIMENTAL
Intervention: eSAID (26-item questionnaire)
Number of subjects: 51
Study: 26208075

Group type: EXPERIMENTAL
Intervention: School-based oral health education program (experimental group)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (no participation in the program)
Number of subjects: 240
Study: 24130433

Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 46
Study: 21357988

Group type: EXPERIMENTAL
Intervention: Thigh-length graduated compression stockings (GCS) in CLOTS Trial 1
Number of subjects: 5632

Group type: EXPERIMENTAL
Intervention: Thigh-length graduated compression stockings (GCS) in CLOTS Trial 2
Number of subjects: 5632

Group type: COMPARATOR
Intervention: No graduated compression stockings (GCS) in CLOTS Trial 1
Number of subjects: 5632

Group type: COMPARATOR
Intervention: Below-knee graduated compression stockings (GCS) in CLOTS Trial 2
Number of subjects: 5632

Group type: EXPERIMENTAL
Intervention: Model based on Trial 2 cohort
Number of subjects: 5632

Group type: COMPARATOR
Intervention: Model tested in Trial 1 cohort
Number of subjects: 5632
Study: 18462734

Group type: EXPERIMENTAL
Intervention: Unidirectional buccoadhesive bromocriptine methylate discs once daily for 1 month
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vaginoadhesive bromocriptine methylate discs once daily for 1 month
Number of subjects: 42
Study: 16573837

Group type: EXPERIMENTAL
Intervention: Transmitral Doppler flow
Number of subjects: 54

Group type: COMPARATOR
Intervention: 2D echo
Number of subjects: 54
Study: 12658365

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 20

Group type: COMPARATOR
Intervention: l-dopa
Number of subjects: 20
Study: 11726036

Group type: EXPERIMENTAL
Intervention: Lactoferrin (20 mg daily for 5 days before surgery)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 46
Study: 9396978

Group type: EXPERIMENTAL
Intervention: Active treatment (n = 13): encasing mattress, box springs, and pillows in allergen impermeable covers; weekly hot water wash of bed linens; replacement of bedroom carpet with polished flooring; and 3% tannic acid spray to living room carpet.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo treatment (n = 10): permeable encasing for bedding, cold water wash, and water spray for carpet.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Active treatment (n = 13) and Placebo treatment (n = 10)
Number of subjects: 23
Study: 7609499

Group type: EXPERIMENTAL
Intervention: sublingual nifedipine 10 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: sublingual lacidipine 4 mg
Number of subjects: 40
Study: 3280158

Group type: EXPERIMENTAL
Intervention: Diltiazem (180 to 360 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 to 120 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination therapy (Diltiazem and Nifedipine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31839530

Group type: EXPERIMENTAL
Intervention: Extended-release albuterol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30973547

Group type: EXPERIMENTAL
Intervention: +NENS
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: +NS
Number of subjects: 600

Group type: COMPARATOR
Intervention: +SE
Number of subjects: 600
Study: 25553871

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system insertion within 6-48 hours after vaginal birth
Number of subjects: 35

Group type: COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system insertion 4-6 weeks after vaginal birth
Number of subjects: 35
Study: 23613501

Group type: EXPERIMENTAL
Intervention: FGF/MV ratios of 0.2, 0.3, 0.4, and 1.0 with initial FD of sevoflurane at 2.2% vol in study 1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tidal volumes of 6, 8, or 10 ml/kg with initial FD of sevoflurane at 2.2% vol in study 2
Number of subjects: 120
Study: 21493621

Group type: EXPERIMENTAL
Intervention: EZ (combined with conventional 7.5 or 8.5 mm single-lumen tube)
Number of subjects: 40

Group type: COMPARATOR
Intervention: DLT (37 or 39 Fr left‐sided DLT)
Number of subjects: 40
Study: 19306149

Group type: EXPERIMENTAL
Intervention: Frequent therapist contact (three e-mails per week)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Infrequent therapist contact (one e-mail per week)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both frequent and infrequent contact
Number of subjects: 57
Study: 16732018

Group type: EXPERIMENTAL
Intervention: 25% calorie restriction (CR)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 12.5% calorie restriction + 12.5% energy expenditure through structured exercise (CREX)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 15% weight loss by a low-calorie diet (LCD) followed by weight maintenance for 6 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (100% of energy requirements)
Number of subjects: 48
Study: 15110928

Group type: EXPERIMENTAL
Intervention: High serum leptin levels at discharge from inpatient treatment
Number of subjects: 18
Study: 11061603

Group type: EXPERIMENTAL
Intervention: BEACOPP chemotherapy (dose-intensified variant, arm 2)
Number of subjects: 858

Group type: COMPARATOR
Intervention: BEACOPP chemotherapy (baseline variant, arm 1)
Number of subjects: 858
Study: 8884052

Group type: EXPERIMENTAL
Intervention: Increased tonal auditory threshold (up to 30 dB) without decrease of the discomfort threshold
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Decreased discomfort threshold (with about 15‐20 dB) at increased tonal auditory threshold (up to 45 dB)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Decreased discomfort threshold at increased (over 50 dB) tonal auditory threshold
Number of subjects: 385

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 385
Study: 1390143

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic limb ulcer therapy (PELUT) device used at home for 3 hours daily for 8 weeks as an adjunct to a wound dressing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic limb ulcer therapy (PELUT) device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3890197

Group type: EXPERIMENTAL
Intervention: Human insulin (recombinant DNA origin)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Iletin II pork insulin
Number of subjects: 88
Study: 31026438

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 96
Study: 29221735

Group type: EXPERIMENTAL
Intervention: Digital thoracic drainage system (group D)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Traditional thoracic drainage system (group T)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Digital thoracic drainage system (group D) in patients with postoperative air leak
Number of subjects: 299

Group type: COMPARATOR
Intervention: Traditional thoracic drainage system (group T) in patients with postoperative air leak
Number of subjects: 299
Study: 26868314

Group type: EXPERIMENTAL
Intervention: Three-dimensional visualization (3DV) model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-dimensional printing (3DP) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional anatomical atlas
Number of subjects: 0
Study: 24280948

Group type: COMPARATOR
Intervention: Sham laser (0 joules/point)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Low dose laser (0.2 J/point)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: High dose laser (0.8 J/point)
Number of subjects: 144
Study: 22496161

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg/d)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 20615494

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU twice a day for 3 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 17604300

Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Lactobacillus casei, L bulgaricus, and Streptococcus thermophilus, 100 g (97 ml) twice a day during antibiotics and for one week after.
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo group received a longlife sterile milkshake.
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Lactobacillus casei, L bulgaricus, and Streptococcus thermophilus.
Number of subjects: 135
Study: 15685041

Group type: EXPERIMENTAL
Intervention: Intracavitary hyperthermia (ICHT) combined with chemotherapy (5‐FU and mitomycin‐C) and radiotherapy.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Chemotherapy (5‐FU and mitomycin‐C) and radiotherapy without ICHT.
Number of subjects: 49
Study: 12109823

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy plus radiotherapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Radiotherapy without cisplatin
Number of subjects: 8
Study: 9989694

Group type: EXPERIMENTAL
Intervention: 1 mg folic acid/d
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0 mg folic acid/d (unsupplemented)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dietary folate intake
Number of subjects: 42
Study: 9503043

Group type: COMPARATOR
Intervention: Daily supplementation with antioxidant vitamins (vitamin C, 120 mg; vitamin E, 30 mg; beta‐carotene, 6 mg) and minerals (selenium, 100 micrograms; zinc, 20 mg)
Number of subjects: 12735
Study: 1756344

Group type: EXPERIMENTAL
Intervention: Analgesic nitrous oxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Carbogen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 0
Study: 6357891

Group type: EXPERIMENTAL
Intervention: Oxaprozin (1200 mg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 30420725

Group type: EXPERIMENTAL
Intervention: High-efficiency (HE: true-HEPA) indoor air filtration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-efficiency (LE: HEPA-type) indoor air filtration
Number of subjects: 40

Group type: COMPARATOR
Intervention: No filter (control)
Number of subjects: 40
Study: 29543106

Group type: COMPARATOR
Intervention: Light/Moderate Walking (prepregnancy)
Number of subjects: 3687

Group type: COMPARATOR
Intervention: Light/Moderate Walking (early pregnancy)
Number of subjects: 3687

Group type: COMPARATOR
Intervention: Yoga Practice
Number of subjects: 3687

Group type: EXPERIMENTAL
Intervention: No Light/Moderate Walking
Number of subjects: 3687
Study: 27007256

Group type: EXPERIMENTAL
Intervention: Scheduled psychological support
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Non-scheduled psychological support
Number of subjects: 77

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 77
Study: 24885267

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (0.5 mls/kg 0.25% levo‐bupivacaine) followed by ropivacaine (0.2% 5 ml/hr‐1) infused via a femoral nerve catheter until 48 hours post‐surgery
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 150
Study: 22632142

Group type: EXPERIMENTAL
Intervention: General practitioners (GPs) managing CVADs in the community
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reasons for using CVADs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Education in CVAD management
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Awareness of existing guidelines
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Primary responsibility for care of CVADs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Challenges identified by GPs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Suggestions to address challenges
Number of subjects: 50
Study: 20980590

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Satiety (prescan meal)
Number of subjects: 0
Study: 18411608

Group type: EXPERIMENTAL
Intervention: Low-energy extracorporeal shock wave therapy (ESWT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 25